Last reviewed · How we verify
d-borneol
d-borneol is a natural compound that acts as a GABA receptor agonist.
d-borneol is a natural compound that acts as a GABA receptor agonist. Used for Pain relief, Inflammation.
At a glance
| Generic name | d-borneol |
|---|---|
| Sponsor | Peking University Third Hospital |
| Target | GABA receptor |
| Modality | Small molecule |
| Therapeutic area | Pain relief, Inflammation |
| Phase | Phase 3 |
Mechanism of action
d-borneol is a chiral molecule that binds to GABA receptors, mimicking the action of the neurotransmitter gamma-aminobutyric acid (GABA). This binding causes a calming effect on the nervous system, leading to its use in various applications.
Approved indications
- Pain relief
- Inflammation
Common side effects
- Dizziness
- Nausea
Key clinical trials
- Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- d-borneol CI brief — competitive landscape report
- d-borneol updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI